52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Sept 21(Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Kissei Pharmaceutical Co Ltd and KYORIN Holdings, Inc. <<<4569.T>>> jointly announced today that KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 21, 2018 to market 'Beova® Tablets 50mg' for the treatment of overactive bladder.
April 23 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it appoints Yoshio Furihata as president, to succeed Masaki Morozumi, effective June 27 .
April 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Rating and Investment Information, Inc. (R&I) withdrew the rating on the company of "A-" -R&I.
Feb 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it completed repurchase of 1.6 million shares of its common stock, for 4.46 billion yen in total, through ToSTNeT-3, on Feb. 13 .
Feb 9 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it will repurchase up to 1.8 million shares, representing 3.7 percent of outstanding, for up to 5.02 billion yen, through ToSTNeT-3, on Feb. 13 .Says it will retire 2.5 million shares (4.6 percent of outstanding) of its common stock on March 9 .
Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .
June 9 (Reuters) - VIFOR PHARMA AG <VIFN.S>::KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA.
Kissei Pharmaceutical Co Ltd <4547.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" – R&I .Rating outlook stable– R&I.
Kyorin Holdings Inc:KYORIN Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. and Kissei Pharmaceutical Co., Ltd. jointly announced a co-development and co-marketing agreement for an overactive bladder medication of KRP-114V (INN: Vibegron) which is being developed by Kyorin in Japan.
KISSEI PHARMACEUTICAL CO LTD:To retire 2,600,000 shares (4.57 pct stake) of its common stock on May 15.Says the total shares outstanding will be 54,311,185 shares after the retirement.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.